04/03/2022at 09:39

Bavarian Nordic expects revenue setback in 2022

Key 2021 figures from Bavarian Nordic’s annual report are in line with projections, but scrape the bottom of previous estimations. 2022 will be a year of investments for the biotech company, which is why an operating deficit is already being forecasted.

by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Biotech company Bavarian Nordic almost made a comeback in 2021 – but not quite.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Analyst: Focus on Bavarian Nordic's 2022 outlook, orders and costs in upcoming report
For subscribers
Bavarian unconcerned by Moderna RSV advance: ”It's completely as expected"
For subscribers
Pfizer's RSV candidate receives FDA special status
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Pharma & biotech

Wegovy prescriptions in the US grow for another week

For subscribers

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers